As the world awaits the development of a vaccine for the novel coronavirus causing Covid-19, reports in the past week of successful treatment of severely ill patients at a Chicago hospital with the antiviral medicine Remdesivir were headlined in the US and caused a bounce on global sharemarkets.
Remdesivir was one of the first medicines identified in lab tests as having the potential to impact SARS-CoV-2. Results from US biotechnology firm Gilead Science’s clinical trials have been eagerly expected as the world looks for positive outcomes which could lead to fast approvals by the Food and Drug Administration and other regulatory agencies.
If safe and effective, it could become the first approved treatment against the disease.
The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease.
All the patients have been treated with daily infusions of…
View original post 697 more words
Utopia, you are standing in it! 
Recent Comments